• The electronic monitoring (“EM”) company won Germany’s national EM  contract, valued at up to $7 million over four years.
• SuperCom displaced a provider that had supplied the country’s EM technology for more than 20 years.
• Germany becomes the ninth nation to adopt SuperCom’s domestic violence solution.
• Contract covers multiple programs, including GPS tracking, domestic violence monitoring, home detention, and alcohol monitoring.

SuperCom (NASDAQ: SPCB), a global provider of secured e-Government, IoT, and cybersecurity solutions, has been awarded a national electronic monitoring (“EM”) contract in Germany, marking a strategic expansion into Europe’s largest economy. The program budget is estimated at $7 million over four years, with actual revenues depending on usage levels, according to a company news release (https://ibn.fm/83moK).

The contract was secured through a competitive tender that included multiple global vendors. For more than two decades, Germany’s EM systems had been provided by the same supplier. SuperCom’s selection reflects a shift in how European governments are approaching offender monitoring and domestic violence prevention.

Germany is recognized as one of Europe’s pioneers in electronic monitoring, with over 25 years of experience in the field. The decision to move away from its longstanding vendor highlights both the maturity of the German market and the demand for more adaptable, technology-driven platforms.

“Securing this award after a highly competitive process is a powerful validation of our technology and execution capabilities globally. This is more than a contract win, it is a strategic milestone that demonstrates how our PureSecurity Suite meets the highest standards for modern public safety solutions,” Chief Executive Ordan Trabelsi said. “We are honored to support Germany’s evolving EM programs with our proprietary, field-proven technology.”

SuperCom will deploy its PureSecurity(TM) Suite, which integrates GPS tracking, RF technology, multi-factor biometrics, and secure communications. The system supports a variety of public safety applications, including domestic violence prevention, home detention, alcohol monitoring, and broader community supervision.

Germany becomes the ninth nation to adopt SuperCom’s domestic violence solution. The platform includes PureProtect(TM), a mobile app that alerts victims if restrictions are breached. The app utilizes advanced zoning, proximity, alerting, and management capabilities to both enforce a safe distance between victims and perpetrators and update the former on the latter’s whereabouts. Together with GPS-enabled PureOne(TM) tracking bracelets and PureMonitor(TM) software for law enforcement, these tools offer a comprehensive framework for safeguarding victims while ensuring offender compliance.

Electronic monitoring has been linked to reduced recidivism in several international studies. Research from Argentina found a 48% reduction in one-year reoffending rates, while studies in Australia and France reported decreases of 28% and 10% respectively. These outcomes suggest EM programs not only improve public safety but can also reduce the economic burden of traditional incarceration.

By offering modular, scalable technology, SuperCom positions itself as a provider capable of supporting both large national projects and smaller regional programs.

The German award builds on SuperCom’s momentum in Europe, where it has secured more than 15 national EM projects. In the United States, the company has added over 30 contracts in the past year alone. Trabelsi emphasized that initial contracts often expand into additional opportunities as governments gain confidence in the technology.

“While this new contract in Germany already spans four programs, we are also excited about the additional opportunities our technology can help unlock as needs evolve,” Trabelsi added. “We look forward to supporting Germany in this important project and further strengthening our role as a trusted partner to governments worldwide seeking innovative and effective public safety solutions.”

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at https://ibn.fm/SPCB

• Hoth Therapeutics (NASDAQ: HOTH) is using Lantern Pharma’s (NASDAQ: LTRN) PredictBBB.ai(TM) platform to accelerate development timelines, reduce risk, and improve candidate selection.
• This technology helps determine whether or not a candidate is able to cross the blood-brain barrier or not, which is a major holdup for many drug development companies.
• Leadership at both Lantern Pharma and Hoth Therapeutics are enthusiastic about the collaboration and how it can help deliver life-changing therapies for patients.

Hoth Therapeutics (NASDAQ: HOTH), a biopharmaceutical company, recently announced that the company is using an AI-powered platform developed by Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotech company and pharma, to streamline and improve the drug development process (https://ibn.fm/VIL67).

The platform, called PredictBBB.ai(TM), is a next-gen AI tool that was designed to help determine whether a drug candidate is able to cross the blood-brain barrier. This is a common bottleneck in drug development, and Lantern Pharma’s platform offers 94% accuracy in predicting whether or not different compounds are able to permeate the blood-brain barrier.

With the help of this cutting-edge platform, Hoth Therapeutics can use AI-powered insights to lessen uncertainty, reduce risk, boost precision, speed up timelines, and improve candidate selection.

The PredictBBB.ai tool is a part of a larger platform being developed by Lantern Pharma, called RADR®, which stands for Response Algorithm for Drug Positioning & Rescue. The platform is used to predict the responses patients may have to different drugs, and also to help in the process of developing target compounds to fight against cancer.

Leadership at both Lantern Pharma and Hoth Therapeutics are enthusiastic about the partnership, and what it means for cancer patients.

Lantern Pharma CEO Panna Sharma said “At Lantern Pharma, we’re very enthused by the early adoption of our PredictBBB.ai platform by innovators like Hoth Therapeutics. This online service, which is a part of our RADR platform, has the potential to be a game-changer in CNS drug development. This cutting-edge AI tool, with its 94% accuracy in predicting blood-brain barrier permeability, is empowering researchers to make faster, smarter decisions, accelerating the path to life-changing therapies for patients worldwide.”

Echoing this excitement, Hoth Therapeutics CEO Robb Knie added that “Our integration of Lantern’s PredictBBB.ai tool aligns with our mission to deliver life-changing therapies while driving efficiency, reducing costs, and unlocking new opportunities for patients and shareholders alike.”

About Lantern Pharma Inc. (NASDAQ: LTRN)

Lantern Pharma Inc. is an oncology-focused, clinical stage pharma that’s concentrating on artificial intelligence, genomics, and machine learning. Applying and expanding cutting-edge AI technology, the company has the mission of delivering precision oncology therapies with reduced costs and timelines.

For more information, visit the company’s website at www.LanternPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

• SuperCom has secured a new electronic monitoring project with a sheriff’s department in Wisconsin, marking the company’s 12th new U.S. state entry since August 2024.
• The company has signed over 30 contracts and 11 reseller partnerships in the U.S. during the same period.
• The project introduces a domestic violence prevention program and may expand into GPS tracking, as the company deploys its PureSecurity(TM) platform, offering modular GPS, RFID, and mobile solutions tailored to public safety needs.
• Research indicates electronic monitoring programs can reduce recidivism rates.

SuperCom (NASDAQ: SPCB), a global provider of secured e-Government, IoT, and cybersecurity solutions, has expanded into its 12th U.S. state through a new electronic monitoring (“EM”) project in Wisconsin. The company announced on September 17 that, in partnership with a Midwest service provider, it will deploy its PureSecurity(TM) EM technology for a sheriff’s department program (https://ibn.fm/QWdMu).

The Wisconsin agency is launching a domestic violence prevention initiative using SuperCom’s system, with plans to expand into GPS-based offender tracking. The selection followed a review of multiple technology providers, with SuperCom chosen for its precision, reliability, and mobile integration. The project is structured under a recurring revenue model, billed monthly based on active daily units.

“This latest win further validates a nationwide shift toward more modern, effective electronic monitoring systems,” said CEO Ordan Trabelsi. “Agencies continue to upgrade from legacy solutions and choose SuperCom with our field-proven technology, rapid deployment capabilities, and track record of delivering measurable improvements in public safety.”

The Wisconsin deployment adds to SuperCom’s record of rapid U.S. expansion. Since August 2024, the company has entered 12 new states, signed over 30 contracts, and formed 11 reseller agreements. These agreements come against a backdrop of rising demand for tools that support alternatives to incarceration. The company’s projects typically focus on offender monitoring, probation programs, and domestic violence prevention.

The recurring revenue model used for these contracts provides predictable income streams. Each new program increases the company’s installed base, which can be expanded through add-on services and complementary solutions.

SuperCom’s EM solutions are built on its PureSecurity platform, a modular system that integrates GPS, RFID, and cloud-based monitoring technologies. The platform is adaptable, allowing jurisdictions to scale programs according to specific needs.

Key offerings include:

• PureOne(TM): a GPS-enabled wearable tracking bracelet.
• PureShield(TM): used in domestic violence cases to enforce exclusion zones and restraining orders.
• PureProtect(TM): a mobile phone and app that alerts victims when restrictions are violated.
• PureMonitor(TM): real-time monitoring software designed for law enforcement agencies.

Additional devices, such as PureCom, PureTag, PureBeacon, and PureTrack, can be deployed to tailor solutions for house arrest, parole, or community-based supervision.

SuperCom’s focus on EM aligns with global evidence showing that monitoring reduces recidivism. Research from Argentina found EM cut the one-year re-offense rate by up to 48%. In Australia, a two-year study showed a 28% reduction, while data from France suggested a 10% decrease in re-offending over five years.

These findings support EM as a cost-effective alternative to incarceration that also aids rehabilitation. Programs like the one now launching in Wisconsin are seen as contributing to both public safety and economic stability.

SuperCom’s model blends technology sales with ongoing service revenue, a structure that has attracted repeat contracts in multiple jurisdictions. The company’s rapid U.S. expansion underscores its ability to win contracts in a competitive market. Each state entry builds brand recognition and strengthens its reseller network, making future adoption more likely. 

“Each win adds to our long-term recurring revenue base and reinforces our expanding footprint. With more than 15 national projects awarded globally and increasing demand for our domestic violence solutions, we’re proud to be the trusted partner governments turn to when seeking to modernize and scale public safety infrastructure,” Trabelsi said. “These achievements come on the heels of record net income and expanded gross margins in the first half of 2025, enabling us to scale and deliver exceptional value to our clients and stakeholders.”

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at https://ibn.fm/SPCB

• Texas-based clinical-stage biotechnology company Lantern Pharma Inc. is developing a number of clinical trials, using its proprietary drug candidates and computational biology and machine learning platform, to target conditions with unmet medical needs
• A recent Type C meeting with the U.S. Food and Drug Administration provided the company with guidance in working through the regulatory pathway and designing the trial for its investigational therapy LP-184/STAR-001, which will seek a means of battling pediatric brain cancers
• Lantern Pharma is also using drug candidates in trials to combat glioblastoma (“GBM”), triple-negative breast cancer, non-small cell lung cancer in non-smokers, non-Hodgkin’s lymphoma, and other tumors
• Lantern’s meeting with the FDA will help it amend its investigational new drug (“IND”) submission for the potential pediatric central nervous system cancer therapy LP-184/STAR-001 and a planned trial launch in Q1 of 2026
• Two of the company’s current trials achieved a complete response in patients during the past quarter

Clinical-stage cancer technology company Lantern Pharma (NASDAQ: LTRN) is preparing for the launch of a trial targeting a rare pediatric disease, planned for Q1 2026, in the wake of the company’s optimistic meeting with the U.S. Food and Drug Administration (“FDA”) to receive critical guidance on the company’s trial design and the FDA’s regulatory pathway.

Lantern Pharma is developing its clinical trial with the hope of demonstrating the efficacy of its investigational therapy LP-184/STAR-001 in combatting central nervous system (“CNS”) cancers, including Atypical Teratoid Rhabdoid Tumor (“ATRT”). The LP-184/STAR-001 therapy is designed to work synergistically with diuretic (water pill) spironolactone (https://ibn.fm/JksRT) and other potential combination regimens in treating the childhood brain cancers classified as unmet medical needs.

Lantern’s program for ATRT has received Rare Pediatric Disease Designation and Orphan Drug Designation from the FDA, and the company is preparing to submit an investigational new drug (“IND”) amendment.

“We are thrilled with the constructive dialogue and positive feedback from our Type C meeting with the FDA,” Lantern President and CEO Panna Sharma stated in the company’s Sept. 3 news release about the meeting (https://ibn.fm/VgPKC). “This guidance not only reinforces our trial design but also highlights the potential of our AI platform, RADR®, in identifying and optimizing combination regimens like spironolactone for these devastating pediatric CNS cancers.”

Lantern aims to transform cancer treatment through the use of artificial intelligence (“AI”) to identify biomarkers related to the cancers, analyzing genomic data from large populations of individuals to understand disease-related genetic variations. The company then aims to progressively use preclinical modeling to accelerate the development of oncology drugs.

The company’s proprietary computational biology and machine learning platform will be used in the planned Phase 1b/2 trial that will enroll pediatric patients across multiple sites, with primary endpoints focused on progression-free survival, overall response rate, and quality-of-life measures.

Lantern is also using LP-184 in a Phase 1a trial for glioblastoma (“GBM”) and advanced solid tumors such as triple-negative breast cancer (“TNBC”). It also is in a Phase 2 trial using its drug candidate LP-300 for treating non-small cell lung cancer (“NSCLC”) in individuals whose cancer is completely unrelated to smoking tobacco. And the company is using its LP-284 drug candidate in a Phase 1 trial for relapsed or refractory non-Hodgkin’s lymphoma (“NHL”) and other solid tumors.

The trial of LP-300 in combination with chemotherapy has resulted in a complete response for a 70-year-old non-smoker with advanced non-small cell lung cancer after three prior lines of therapy had failed.

“This quarter we observed complete responses in patients across two of our clinical trials, delivering meaningful patient benefit and providing further validation of both the mechanisms and therapeutic potential of our drug candidates,” Sharma said last month (https://ibn.fm/bHsie). “Simultaneously, our team is transforming our AI platform into functional, accessible modules for the broader oncology community. These parallel advances mark a pivotal inflection point in our clinical and technological evolution.”

For more information, visit the company’s website at www.LanternPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

Maximizing Gold Leverage While Minimizing Risk

Gold has surged to new record highs – recently surpassing $3,780 per ounce – as investors worldwide turn to the metal’s proven role as a hedge against inflation, currency weakness, and financial-market volatility (ibn.fm/29CUk). With expectations of rate cuts, central bank demand, and softer global growth, analysts see further upside.  In this environment, quality gold mining companies offer powerful leverage, where even modest price increases can generate outsized equity returns.

West Vault Mining (TSX.V: WVM) (OTCQX: WVMDF), a Nevada-focused gold company, has positioned itself to capture this opportunity while carefully controlling downside risk. The company’s strategy is simple: deliver low-risk exposure to high-margin gold ounces in one of the world’s safest, most mining-friendly jurisdictions.

A De-Risked, Permitted Gold Project in Nevada

At the center of West Vault’s strategy is the Hasbrouck Gold Project (ibn.fm/Fz6I1), located near Tonopah, Nevada—the heart of America’s most prolific gold-producing region. Nevada is responsible for over 70% of U.S. gold production, underpinned by world-class geology, modern infrastructure, and a legal framework supportive of mining (ibn.fm/bTeHj).

Unlike many junior miners, West Vault has already advanced Hasbrouck well beyond the conceptual stage:

• All major permits secured for mine development.
• Pre-feasibility study completed, demonstrating strong project economics.
• Strategic location along an established mining corridor, reducing both cost and infrastructure risk.

This disciplined approach translates into lower political, permitting, and execution risk, allowing shareholders to maintain full exposure to rising gold prices without the uncertainties often associated with early-stage exploration.

Proven Leadership With Technical and Financial Strength

West Vault is led by a management and board team whose experience spans mine construction, operations, finance, and capital markets (ibn.fm/VxUSG):

• Sandy McVey, CEO & COO – A Professional Mining Engineer and Project Management Professional with 30+ years in mine construction and operations worldwide.
• Frank R. Hallam, CFO & Director – A Chartered Professional Accountant and co-founder with decades of experience founding and financing successful North American mining companies.
• Peter Palmedo, Chair & Director – Founder of Sun Valley Gold LLC, bringing deep investment expertise and strategic market insight.

This blend of operational credibility and financial acumen provides the company with a strong foundation for executing its development strategy and maintaining investor confidence.

Positioned for a Bullish Gold Cycle

For investors considering gold exposure, West Vault represents a speculative play with upside potential tied to rising gold prices and favorable jurisdictional exposure. If the gold cycle continues and West Vault follows its strategy, the leverage to gold has potential to generate meaningful returns for shareholders.

As the gold market continues its record-setting run, West Vault Mining is well placed to generate value for shareholders – capturing the upside of rising gold prices while mitigating many of the risks that often accompany early-stage mining ventures.

For more information, visit the company’s website at www.WestVaultMining.com.

NOTE TO INVESTORS: The latest news and updates relating to WVMDF are available in the company’s newsroom at ibn.fm/WVMDF

• The White House’s recent proclamation targets copper imports with tariffs to bolster domestic production and national security
• Interior Department proposes adding copper to the U.S. critical minerals list, potentially unlocking federal funding and streamlined permitting for domestic projects
• Trilogy Metals’ Upper Kobuk Mineral Projects in Alaska contain high-grade copper, cobalt, zinc, and other defense-critical metals

The convergence of market demand, national security priorities, and federal policy is reshaping the U.S. copper landscape. Copper, essential for defense systems, infrastructure, and emerging technologies, has become a focal point of strategic concern. The combination of executive action and critical minerals policy highlights the urgent need to secure domestic sources, a development that positions Trilogy Metals (NYSE American: TMQ) (TSX: TMQ) at the center of both economic and national security considerations.

Federal Action Elevates Domestic Copper

In late July 2025, the White House issued a proclamation under Section 232 of the Trade Expansion Act, imposing tariffs of up to 50% on semi-finished and derivative copper products imported into the United States. The administration cited risks to national security from overreliance on foreign supply, particularly as a single country dominates global smelting and refining. Copper’s role across the Department of Defense, including aircraft, vehicles, ships, missiles, and ammunition, was highlighted as critical to maintaining technological and military readiness.

These tariffs aim to stimulate domestic production, incentivize investment in U.S. copper fabrication, and reduce vulnerability to supply chain disruptions. The proclamation also outlines phased domestic sales requirements and export controls for high-quality copper scrap, further bolstering U.S. industrial resilience.

Critical Minerals Listing Expands Support

Complementing tariff measures, the Interior Department proposed adding copper to the draft 2025 critical minerals list. Inclusion would make eligible projects potentially competitive for federal funding, streamlined permitting, and protection from certain import-related fees. Copper’s draft designation underscores its strategic importance amid rising domestic electricity demand, the growth of data centers, and electrification of transportation.

Secretary of the Interior Doug Burgum noted that the draft list provides a roadmap to reduce U.S. dependence on imports while expanding domestic production. Public comment on the proposal is open for 30 days, with the final list expected to further clarify the government’s priorities for supporting strategic mining projects.

Trilogy Metals’ Upper Kobuk Mineral Projects

Trilogy Metals operates through a 50/50 joint venture with South32 at the Upper Kobuk Mineral Projects in Alaska’s Ambler Mining District. The Arctic deposit contains 46.7 million tonnes of probable reserves grading 2.11% copper, 2.9% zinc, and 0.56% lead, complemented by 0.42 g/t gold and 31.8 g/t silver, with a 2023 feasibility study estimating a $1.5 billion pre-tax NPV.

Nearby, the Bornite copper-cobalt project adds an inferred resource of 6.5 billion pounds of copper. Together, Arctic and Bornite offer the potential for a multi-decade mining operation supplying metals essential to defense applications, grid storage, and clean energy technologies – anchored in a high-grade, stable jurisdiction.

Infrastructure as a Strategic Asset

The proposed 211-mile Ambler Access Road, connecting Trilogy’s projects to Alaska’s highway system, has gained strategic significance under new federal policies. Once viewed primarily as economic infrastructure, it now aligns with national security objectives by enabling reliable access to domestic critical minerals. A partnership state-owned corporation Alaska Industrial Development and Export Authority provide technical expertise and community collaboration essential for advancing both permitting and operational readiness.

Market Dynamics Reinforce Policy

Global copper demand continues to rise due to electrification, renewable energy deployment, and the expansion of data centers and AI infrastructure. At the same time, global supply growth is constrained by declining ore grades, extended development timelines, and geopolitical dependencies. Trilogy Metals’ high-grade Arctic and Bornite deposits sit at the nexus of policy and market demand, offering both strategic and economic value.

Strategic Outlook

The intersection of tariffs, critical mineral designation, and strong domestic demand places Trilogy Metals in a unique position. With federal support and infrastructure planning advancing, the company’s Upper Kobuk Mineral Projects could evolve into vital domestic sources of critical minerals, contributing directly to U.S. industrial and defense resilience. As the government continues to emphasize domestic supply security, Trilogy’s Arctic and Bornite deposits may increasingly be seen not only as high-quality mining assets but also as strategic national resources.

For more information, visit www.TrilogyMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to TMQ are available in the company’s newsroom at ibn.fm/TMQ

• Strawberry Fields REIT, Inc., is a self-administered real estate investment trust, focused on the acquisition of properties that are leased out to skilled nursing and other healthcare businesses
• While appearing on The Bell2Bell Podcast, the company’s CEO, Moishe Gubin, reflected on the strides made thus far, the milestones achieved, and the company’s future
• Most notably, Gubin noted the company distributes less than 50% of its AFFO, with the remaining 50% allocated to additional asset purchases which has led to the growth of its AFFO per share of 11% annually
• He continued to reiterate the company’s commitment to building facilities for America’s rapidly increasing aging population

Strawberry Fields REIT (NYSE: AMERICAN: STRW), a self-administered real estate investment trust engaged in the ownership, acquisition, and leasing of skilled nursing and specific other healthcare-related properties, is celebrating 10 years of operation. While appearing on The Bell2Bell Podcast, CEO Moishe Gubin reflected on the company’s success, the milestones it has achieved, and where the company is headed going forward (https://ibn.fm/A1kOf).

Notably, the company has demonstrated impeccable financial discipline and consistency. Gubin noted that the company only distributes 45% to 50% of its Adjusted Funds From Operation (“AFFO”), with the remaining 50% allocated to additional asset purchases, a move that has led to the consistent growth of its value per share at an annual rate of 11%.

“I think our stock is perfect for a more conservative investment with a better yield,” he noted. “We only distribute 45% or 50%. The other 50% is used to buy more assets, and therefore we are growing the AFFO per share at an 11% clip annually,” he added (https://ibn.fm/A1kOf).

This level of success, Gubin noted, can be attributed to the company’s leadership’s understanding of the market, particularly given their operational backgrounds. It’s important to note that the company does not operate these centers but rather acquires and develops appropriate properties that are then leased out to skilled nursing and other healthcare businesses. Gubin and his business partner and Board Member, Michael Blisko, were able to recognize the many intricacies of the healthcare facility business – what works best, and how to address challenges that arise. 

As a result, in its 10+ years of operation, having refined its company evaluation to a science, Strawberry Fields has never seen a missed rent payment, collecting 100% of its rents.

“We evaluate a company as if we were going to be operating it: what deal would we make, how would we buy, what kind of services would we provide?” noted Gubin. “It’s an advantage, because if something goes bad, we can stabilize it and fix a problem before it becomes a big loss,” he added (https://ibn.fm/A1kOf).

Gubin noted that collectively, all these aspects have played a key role in Strawberry Fields’ growth. Today, the company has facilities spread across 10 states, primarily comprised of skilled nursing facilities, a few hospitals, and assisted living facilities. Gubin further noted that the company’s future looks bright and continues to affirm its commitment to owning and leasing facilities for America’s growing aging population.

For company information, visit the company’s website at www.StrawberryFieldsREIT.com

To hear the episode and subscribe for future podcasts, please visit Podcast.Bell2Bell.com

NOTE TO INVESTORS: The latest news and updates relating to STRW are available in the company’s newsroom at https://ibn.fm/STRW

• SEGG Media has recently expanded its offering by launching SEGG Digital and SEGG Productions.
• The company also created a new corporate website to position itself as a forward-thinking brand amid the beginning of their next phase of growth.
• It also recently had representatives from its executive team in Nashville for the season finale of IndyCar, to support the SEGG Media-backed drivers, finalized sponsorships, and to kick the tires on the 2026 SEGG Elite Driver Program.
• SEGG Media kicked off the next stage of its progression thanks to strategic acquisitions, strong capital, and global expansion.

On the heels of its rebranding, SEGG Media (NASDAQ: SEGG, LTRYW) has made several recent announcement showcasing its growth and expansion as an organization.

The company recently launched two new operations: SEGG Digital and SEGG Productions. These launches are focused on expanding brand influence, growing the SEGG Media audience, and creating new sources of revenue.

SEGG Digital is the new global marketing arm for the organization, and will work on various social media strategies, influencer marketing initiatives, and more. On the other hand, SEGG Productions will be all about telling original stories across industries like music, entertainment, and lifestyle.

In addition to launching these new arms of SEGG Media, the company also recently revealed a new corporate website. The new branding, kicking off with seggmediacorp.com, will serve as a digital hub for the organization, providing a portal for stakeholders to access the company’s corporate identity, provide transparency and direct access to their portfolio of brands. 

The organization also had some executives head to Nashville to attend the Borchetta Bourbon Music City Grand Prix, which was the final race of the 2025 INDYCAR season. This included CEO, President, and Chairman Matthew McGahan, COO Gregory Potts, and Board Director Warren Macal.

The group was there to support the three SEGG Media-backed drives (Callum Ilott, Louis Foster, and Seb Murray), work on future sponsorships, and finalize the Elite Driver Program for the 2026 season.

Finally, SEGG Media recently announced it has moved into the next step of its progression as a company. Backed by $450 million in financing, the company is expecting to make numerous acquisitions to speed up market penetration and have strategic partnerships to expand its brand across sports, entertainment, media, and more.

The organization is also focusing more on immersive fan engagement and AI-driven experiences and is expanding into new international markets in the Middle East, Europe, and the Americas.

SEGG Media Corp. is a global sports, entertainment, and gaming organization that’s all about connecting people to experiences. The company owns and operates a portfolio of impressive digital assets like Sports.com, Lottery.com, and Concerts.com.

For more information, visit the company’s website at SEGGMediaCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to SEGG are available in the company’s newsroom at https://ibn.fm/SEGG

• Soligenix is positioning itself to expand its presence in dermatology with a novel therapeutic option for one of the most prevalent autoimmune skin conditions.
• The company’s current study aims to further assess safety and biological activity of SGX302, as well as generate additional data to guide larger studies.
• SGX302 has already demonstrated positive results in a phase 1/2 pilot study.

Psoriasis remains a persistent challenge for millions of patients worldwide, and promising new treatments are being closely watched by the medical and investor communities alike. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases and inflammatory conditions, is advancing its treatment candidate, SGX302, in a phase 2a clinical trial for mild-to-moderate psoriasis. The company has already seen encouraging signals in earlier proof-of-concept work, and with its current study underway, Soligenix is positioning itself to expand its presence in dermatology with a novel therapeutic option for one of the most prevalent autoimmune skin conditions.

The psoriasis trial, officially registered as NCT05442190, is designed as a phase 2a open-label study evaluating SGX302, a synthetic hypericin formulation, in patients with mild-to-moderate disease. Building on earlier positive phase 1/2 proof-of-concept data, this current study aims to further assess safety and biological activity, as well as generate additional data to guide larger studies. According to Soligenix, positive outcomes have already been observed in select patients within the first two cohorts of the trial, giving the company confidence in the potential of SGX302 (https://ibn.fm/dqtUu).

Psoriasis is not just a cosmetic concern; it is a chronic, inflammatory condition with significant physical and psychological impact. The American Academy of Dermatology estimates that more than 7.5 million people in the United States are affected by psoriasis, with millions more across Europe and globally (https://ibn.fm/nTANg). Within this group, a large percentage experience mild-to-moderate disease, representing a substantial addressable market for effective treatments.

Existing therapies can be expensive or carry safety concerns when used long-term, creating a demand for novel approaches that balance efficacy with tolerability. Leveraging the same synthetic hypericin platform as Soligenix’s HyBryte(TM) for cutaneous T-cell lymphoma, SGX302 offers a unique mechanism that may deliver sustained benefits without the drawbacks associated with some conventional systemic or biologic therapies.

Soligenix reports that SGX302 has already demonstrated positive results in a phase 1/2 pilot study. In the current phase 2a study, markers of clinical success have been noted in two of the four patients treated in cohort 2. While results remain preliminary, they add to a growing body of evidence that SGX302 could become a viable option in a global psoriasis treatment market that Soligenix notes is projected to reach as much as $67 billion by 2030 (https://ibn.fm/TB3hi). Importantly, the company’s progress with SGX302 builds on its expertise with synthetic hypericin, already advanced into late-stage development in other dermatologic conditions, providing a degree of de-risking to the psoriasis program.

For investors, the potential here is twofold. First, the psoriasis program addresses a widespread, mainstream condition with substantial commercial upside. Second, Soligenix has a pipeline strategy that leverages synergies across its biotherapeutics business segment. Success with SGX302 would not only open the door to a large market but also validate the company’s broader approach of applying synthetic hypericin across multiple indications. With its dual business model that includes both biotherapeutics and public health solutions, Soligenix has benefited from diversification, nondilutive government support, and opportunities for near- and long-term value creation.

Expectations for ongoing results remain high. The phase 2a trial continues enrollment, with expanded clinical readouts anticipated in the near-term. If outcomes align with early signals, Soligenix may advance into a more definitive study designed to secure regulatory guidance and pave the way toward commercialization. Given the strong safety data to date and the unmet need for new and safer psoriasis treatments, SGX302 could be a meaningful addition to the treatment landscape if development milestones are successfully achieved.

Soligenix’s track record in advancing rare-disease therapies, along with its experience in managing complex regulatory pathways, positions the company well to continue making progress in this space. As psoriasis patients and physicians alike seek more options that are effective, safe and accessible, the company’s ongoing trial of SGX302 offers hope for an innovative alternative. For investors, the unfolding results of this trial provide a critical catalyst, underscoring why Soligenix’s work in psoriasis is a story worth following.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• CMS proposal keeps CT radiation quality measure voluntary, highlighting ongoing debate around dose safety and image quality
• Izotropic’s IzoView breast CT system engineered to deliver low-dose, high-resolution 3D imaging, aligning with future regulatory and clinical priorities
• Company launches new FAQ page to enhance transparency for investors, clinicians, and decision-makers

In medical imaging, technology often races ahead of regulation. A recent proposal from the Centers for Medicare & Medicaid Services (CMS) underscores this tension: the agency is opting not to mandate radiation dose tracking for CT scans by 2027. While the decision reflects operational challenges hospitals face in meeting such requirements, it also highlights a growing consensus: patients, providers, and regulators all want sharper images with lower radiation exposure.

As CT utilization continues to expand, the industry sits at a crossroads. Balancing image clarity with radiation safety is no longer just a technical issue; it is becoming central to policy, reimbursement, and patient advocacy. For innovators in breast imaging, this is both a challenge and an opportunity.

Izotropic’s Purpose-Built Approach

Izotropic (CSE: IZO) (OTCQB: IZOZF) is positioning itself within this evolving dialogue. The company’s flagship product, IzoView, is a dedicated breast CT system designed to address the dual goals of radiation dose reduction and ultra-high-resolution imaging.

IzoView offers true 360-degree 3D imaging without compression, creating a more comfortable experience for patients while and may improve diagnostic confidence for clinicians. Its design prioritizes radiation efficiency without sacrificing image quality, a combination that speaks directly to the concerns driving CMS deliberations and radiology community debates.

By engineering a system that anticipates tomorrow’s quality measures, Izotropic may offer hospitals and clinics a future-ready solution in an environment where dose tracking, safety, and diagnostic precision are increasingly non-negotiable.

Transparency and Engagement Through New FAQ Resource

In parallel with its technological development, Izotropic is also working to strengthen communication with stakeholders. The company recently announced the launch of a Frequently Asked Questions (FAQ) page on its corporate website.

This resource provides investors, analysts, clinicians, and healthcare decision-makers with clear information about IzoView’s positioning, imaging workflow, and comparisons to mammography, ultrasound, and MRI. It also explains the clinical relevance of dense breast tissue, a key challenge in cancer detection, and underscores Izotropic’s exclusive commercialization rights for breast CT technology developed at the University of California, Davis.

Optimized for search engines and AI platforms, the FAQ page enhances discoverability and supports outreach to media, clinical audiences, and investors. Importantly, it reflects the company’s commitment to transparency as it advances through clinical trials, FDA review, and eventual commercialization.

Market Implications in Breast Imaging

The breast imaging market remains dominated by mammography, despite its limitations in patients with dense breast tissue. Supplemental methods such as ultrasound and MRI fill some gaps but carry trade-offs in cost, accessibility, or workflow efficiency.

IzoView’s combination of non-compression imaging, high-resolution detail, and radiation management creates a differentiated option. For hospitals navigating voluntary-but-encouraged CMS reporting measures, investing in technologies engineered for higher standards could mitigate future regulatory risk while improving patient outcomes.

As regulators, clinicians, and patient advocates continue to press for safer, higher-quality imaging, Izotropic’s technology arrives at a timely moment. If dose reporting becomes mandatory in the future, as many experts believe it eventually will, hospitals adopting systems like IzoView may be better prepared to comply without major workflow disruption.

Positioning for Long-Term Growth

Izotropic’s dual focus on innovation and transparent communication reinforces its strategic positioning. On the technical side, IzoView addresses both immediate clinical needs and anticipated regulatory requirements. On the communication side, the new FAQ page strengthens investor confidence and equips healthcare decision-makers with essential knowledge.

With its regulatory pathway in progress, Izotropic is aligning itself with both market demand and policy direction. Whether or not CMS makes dose reporting mandatory in the near term, the broader push toward radiation safety and high-resolution imaging is unlikely to reverse course.

For investors, this alignment between regulatory trends and clinical needs represents a notable opportunity. Izotropic is not simply developing imaging hardware; it is building a platform that anticipates where the standards of care are heading.

For more information, visit the company’s website at www.IzoCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at ibn.fm/IZOZF